Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.91 USD
-0.04 (-1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.90 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Organogenesis falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 104 | 103 | 115 | 85 | 60 |
Receivables | 82 | 89 | 82 | 57 | 39 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 28 | 25 | 25 | 28 | 23 |
Other Current Assets | 10 | 5 | 5 | 5 | 3 |
Total Current Assets | 225 | 223 | 227 | 174 | 126 |
Net Property & Equipment | 116 | 102 | 79 | 60 | 47 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 28 | 30 | 32 | 0 | 0 |
Intangibles | 45 | 50 | 54 | 59 | 46 |
Deposits & Other Assets | 6 | 2 | 2 | 1 | 1 |
Total Assets | 460 | 449 | 443 | 294 | 221 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 3 | 17 | 0 |
Accounts Payable | 31 | 32 | 29 | 23 | 28 |
Current Portion Long-Term Debt | 5 | 5 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 0 | 0 | 4 | 3 |
Accrued Expenses | 30 | 26 | 37 | 24 | 23 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 1 | 5 |
Total Current Liabilities | 81 | 75 | 82 | 68 | 60 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 2 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 61 | 66 | 71 | 53 | 83 |
Non-Current Capital Leases | 2 | 0 | 0 | 11 | 14 |
Other Non-Current Liabilities | 1 | 1 | 2 | 13 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 181 | 184 | 201 | 148 | 165 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 320 | 311 | 302 | 299 | 227 |
Retained Earnings | -41 | -45 | -60 | -153 | -171 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 279 | 266 | 242 | 146 | 56 |
Total Liabilities & Shareholder's Equity | 460 | 449 | 443 | 294 | 221 |
Total Common Equity | 279 | 266 | 242 | 146 | 56 |
Shares Outstanding | 132.00 | 130.90 | 128.60 | 107.70 | 94.70 |
Book Value Per Share | 2.11 | 2.03 | 1.88 | 1.36 | 0.59 |
Fiscal Year End for Organogenesis falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 89 | 104 | 99 | 90 |
Receivables | NA | 96 | 82 | 89 | 94 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 28 | 28 | 28 | 25 |
Other Current Assets | NA | 14 | 10 | 10 | 8 |
Total Current Assets | NA | 227 | 225 | 226 | 216 |
Net Property & Equipment | NA | 114 | 116 | 118 | 112 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 28 | 28 | 30 | 30 |
Intangibles | NA | 44 | 45 | 46 | 47 |
Deposits & Other Assets | NA | 7 | 6 | 1 | 1 |
Total Assets | NA | 458 | 460 | 463 | 450 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 5 |
Accounts Payable | NA | 23 | 31 | 27 | 27 |
Current Portion Long-Term Debt | NA | 5 | 5 | 5 | 0 |
Current Portion Capital Leases | NA | 1 | 1 | 1 | 0 |
Accrued Expenses | NA | 40 | 30 | 35 | 28 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 83 | 81 | 81 | 73 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 59 | 61 | 62 | 63 |
Non-Current Capital Leases | NA | 2 | 2 | 2 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 180 | 181 | 186 | 179 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 321 | 320 | 317 | 315 |
Retained Earnings | NA | -43 | -41 | -40 | -44 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 278 | 279 | 277 | 271 |
Total Liabilities & Shareholder's Equity | NA | 458 | 460 | 463 | 450 |
Total Common Equity | 0 | 278 | 279 | 277 | 271 |
Shares Outstanding | 132.50 | 131.90 | 132.00 | 131.30 | 131.20 |
Book Value Per Share | 0.00 | 2.11 | 2.11 | 2.11 | 2.07 |